What is the price target for BAK stock?
15 analysts have analysed BAK and the average price target is 4.67 USD. This implies a price increase of 15.3% is expected in the next year compared to the current price of 4.05.
BRASKEM SA-CLASS A- ADR (BAK) Forecast, Price Target & Analyst Ratings
NYSE:BAK • US1055321053
Current stock price
4.05 USD
+0.17 (+4.38%)
At close:
4.05 USD
0 (0%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRASKEM SA-CLASS A- ADR (BAK).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -R$4.99
- Revenue Estimate
- 18.013B
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.67
Upside
+ 15.30%
From current price of $4.05 to mean target of $4.67, Based on 15 analyst forecasts
Low
$3.10
Median
$4.30
High
$9.66
Price Target Revisions
1 Month
0.00%
3 Months
0.68%
Price Target Summary
15 Wall Street analysts provided a forecast for the next 12 months for BAK. The average price target is 4.67 USD. This implies a price increase of 15.3% is expected in the next year compared to the current price of 4.05.
The average price target has been revised upward by 0.68% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
49.33%
BAK was analyzed by 15 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about BAK.
In the last month the buy percentage fell by 24 points. So the trust of analysts is decreasing.
BAK was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-26 | UBS | Downgrade | Buy -> Neutral |
| 2025-08-27 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-09-18 | UBS | Upgrade | Neutral -> Buy |
| 2024-09-10 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-08-20 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-05-24 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023-07-05 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-08 | ScotiaBank | Upgrade | Sector Perform -> Sector Outperform |
| 2022-08-15 | ScotiaBank | Downgrade | Sector Perform -> Sector Underperform |
| 2022-01-26 | HSBC | Upgrade | Hold -> Buy |
| 2021-12-14 | Santander | Downgrade | Buy -> Hold |
| 2021-09-21 | B of A Securities | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -R$4.99
- Revenue Estimate
- 18.013B
- Revenue Q2Q
- -5.95%
- EPS Q2Q
- 64.73%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BAK is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -4.99 USD and the consensus revenue estimate is 18.01B USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2025 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 96.519B -8.62% | 70.569B -26.89% | 77.411B 9.70% | 75.487B -2.49% | 79.564B 5.40% | 86.415B 8.61% | |
| EBITDA YoY % growth | 10.52B -65.94% | 4.761B -54.74% | 6.171B 29.62% | 3.75B -39.23% | 6.559B 74.91% | 9.002B 37.25% | |
| EBIT YoY % growth | 5.787B -78.34% | -445M -107.69% | 1.221B 374.38% | -1.628B -233.32% | 1.218B 174.82% | 2.483B 103.86% | |
| Operating Margin | 6.00% | -0.63% | 1.58% | -2.16% | 1.53% | 2.87% | |
| EPS YoY % growth | -0.82 -102.32% | -10.87 -1,232.35% | -28.40 -161.22% | -4.27 84.98% | -9.02 -111.31% | -2.12 76.44% |
All data in BRL
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -4.99 64.73% | -2.18 -224.07% | -2.29 -193.15% | -1.85 -1,445.00% | -1.96 60.81% |
| Revenue Q2Q % growth | 18.013B -5.95% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 823.85M -81.31% | 1.745B 37.73% | 1.912B 4.08% | 2.046B 92.84% | 2.052B 149.07% |
| EBIT Q2Q % growth | -370.089M 31.72% | N/A | N/A | N/A | N/A |
All data in BRL
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.40%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1.99%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
90.95%
EBIT Next 5 Year
N/A
BRASKEM SA-CLASS A- ADR / BAK Forecast FAQ
Can you provide the upcoming earnings date for BRASKEM SA-CLASS A- ADR?
BRASKEM SA-CLASS A- ADR (BAK) will report earnings on 2026-05-12.
What are the consensus estimates for BAK stock next earnings?
The consensus EPS estimate for the next earnings of BRASKEM SA-CLASS A- ADR (BAK) is -4.99 USD and the consensus revenue estimate is 18.01B USD.
What is the expected long term growth rate for BAK stock?
The expected long term growth rate for BRASKEM SA-CLASS A- ADR (BAK) is 1.99%.